Supplementary Materials

Supplementary Material for:

A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants

Qing Zhu,* Jason S. McLellan, Nicole L. Kallewaard, Nancy D. Ulbrandt, Susan Palaszynski, Jing Zhang, Brian Moldt, Anis Khan, Catherine Svabek, Josephine M. McAuliffe, Daniel Wrapp, Nita K. Patel, Kimberly E. Cook, Bettina W. M. Richter, Patricia C. Ryan, Andy Q. Yuan, JoAnn A. Suzich*

*Corresponding author. Email: suzichj{at} (J.A.S.); zhuq{at} (Q.Z.)

Published 3 May 2017, Sci. Transl. Med. 9, eaaj1928 (2017)
DOI: 10.1126/scitranslmed.aaj1928

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Alignment of VH amino acid sequences of D25 and MEDI8897* with their unmutated common ancestor sequences.
  • Fig. S2. Gel filtration of soluble prefusion RSV F with MEDI8897* Fab.
  • Fig. S3. Binding of D25 variants to RSV F A2 determined by SPR.
  • Fig. S4. Comparison of prefusion-stabilized F derived from subtypes A and B.
  • Fig. S5. Binding of MEDI8897* to RSV F B9320 variants determined by SPR.
  • Fig. S6. Simulated palivizumab serum PK profile in infants (gestational age, 29 to 35 weeks) after five monthly 15 mg/kg intramuscular doses.
  • Table S1. Crystallographic data collection and refinement statistics.
  • Table S2. The frequency of conserved amino acid residues in the F protein of RSV A and B viruses within the MEDI8897* binding site.
  • Table S3. Comparison of the antiviral activities of MEDI8897* and palivizumab in the cotton rats infected with RSV B isolate containing K65Q and S211N.
  • Table S4. Comparison of the antiviral activities of MEDI8897* and MEDI8897 in vitro.
  • References (4250)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S5 (Microsoft Excel format). Primary data.